ClinicalThought
View More
No therapies are FDA approved for NASH, but I believe metabolic, inflammatory, and fibrotic aspects of NASH will all shape its management.
Manal F. Abdelmalek, MD, MPH
Released: October 4, 2019
Why the path to HCV elimination must reach PWID.
Oluwaseun Falade-Nwulia, MBBS, MPH
Released: October 14, 2019
We must stay the course to eliminate HBV as a public health threat.
Paul Y. Kwo, MD
How long should patients with chronic hepatitis B be treated with nucleos(t)ide analogues? When should we treat patients with immune-tolerant hepatitis B? Here’s my take.
Paul Y. Kwo, MD
How can providers ensure that vulnerable populations are linked to HCV testing and care? Here’s my take on what we should be doing in our practice.
Oluwaseun Falade-Nwulia, MBBS, MPH
Released: December 18, 2019
Here’s my take on bariatric surgery, noninvasive testing, and endpoints in patients with NASH.
Manal F. Abdelmalek, MD, MPH
Released: January 16, 2020
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA
Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.
CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.